Zalviso FDA Approval Status
FDA Approved: No
Brand name: Zalviso
Generic name: sufentanil
Dosage form: Sublingual Microtablet System
Company: AcelRx Pharmaceuticals, Inc.
Treatment for: Pain
Zalviso (sufentanil sublingual microtablet system) is a patient-activated, non-invasive analgesic system for the management of moderate-to-severe acute pain in adult patients in the hospital setting.In July 2014, AcelRx Pharmaceuticals, Inc. announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Zalviso.
Development Timeline for Zalviso
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.